Skip to content

US · HELP · BIOTECHNOLOGY

Cybin Inc. Common Stock (HELP) intrinsic value and stock valuation

$6.11as of 2026-11-21 · Mkt cap 652.69M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cybin Inc. Common Stock DCF and intrinsic value

InvestorsCraft values HELP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HELP’s statements →

Cybin Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Toronto, ON M5X 1C9 helus.com

How the business is doing

Fiscal 2017–2026, USD

Revenue
-$-44.68M
20172026
Net income
-$-147.05M
20172026
Free cash flow
-$-133.79M
20172026
Total equity
$232.2M+21.9% 5y CAGRd
20172026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2017–2026, USD
20262025202420232022
Revenue-$-44.68M$470K$0.00$250K$170K
Operating income-$-141.68M-$-143.15M-$-78.84M-$-51.52M-$-63.84M
Net income-$-147.05M-$-113.14M-$-78.08M-$-47.49M-$-67.63M
EPSd-$-4.23M-$-5.6M-$-3.9M-$-9.73M-$-15.37M
Operating cash flow-$-132.42M-$-101.3M-$-68.91M-$-47.43M-$-45.21M
Capital expenditure-$-1.36M-$-1.97M-$-710K-$-3.31M-$-520K
Free cash flow-$-133.79M-$-103.27M-$-69.62M-$-50.74M-$-45.73M
Total assets$252M$258.6M$302M$53.9M$84.1M
Total debt$0.00$0.00$290K$0.00$0.00
Net debt-$-157.78M-$-135.02M-$-208.7M-$-16.63M-$-53.64M
Total equity$232.2M$237.2M$291.9M$48.2M$76.2M
Cash and short-term investments$157.8M$135M$209M$16.6M$53.6M
Income statement
20262025202420232022
Revenue-$-44.68M$470K$0.00$250K$170K
Cost of revenue$120K$470K$0.00$250K$170K
Gross profit-$-44.8M$0.00$0.00$0.00$0.00
Research and development expenses$86M$54.9M$32.4M$25.5M$17.6M
Selling, general and administrative expenses$56M$88.2M$46.5M$26M$46.3M
Other expenses-$-45.16M$0.00$0.00$0.00$0.00
Operating expenses$96.9M$143.2M$78.8M$51.5M$63.8M
Cost and expenses$97M$143.6M$78.8M$51.8M$64M
Interest income$5.07M$8.29M$620K$600K$240K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$120K$210K$420K$250K$170K
Ebitda-$-141.56M-$-142.94M-$-78.41M-$-51.27M-$-63.67M
Operating income-$-141.68M-$-143.15M-$-78.84M-$-51.52M-$-63.84M
Total other income/expenses, net$84M$29.5M$760K$3.78M-$-3.96M
Income before tax-$-57.69M-$-113.61M-$-78.08M-$-47.74M-$-67.8M
Income tax expense$89.4M-$-470K$0.00-$-250K-$-170K
Net income-$-147.05M-$-113.14M-$-78.08M-$-47.49M-$-67.63M
Weighted average shares outstanding$34.8M$20.2M$20M$4.88M$4.4M
Weighted average diluted shares outstanding$34.8M$20.2M$20M$4.88M$4.4M
Balance sheet
20262025202420232022
Cash and short-term investments$157.8M$135M$209M$16.6M$53.6M
Net receivables$5.03M$5.88M$4.48M$3.05M$2.1M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$185.1M$166M$218.5M$23.2M$58.4M
Property, plant and equipment, net$200K$140K$550K$450K$490K
Goodwill and intangible assets$66.7M$92.5M$82.9M$30.3M$25M
Long-term investments$0.00$0.00$0.00$0.00$240K
Total non-current assets$66.9M$92.7M$83.5M$30.7M$25.7M
Total assets$252M$258.6M$302M$53.9M$84.1M
Accounts payable$0.00$21.4M$9.8M$5.66M$5.26M
Short-term debt$0.00$0.00$290K$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$19.4M$21.4M$10.1M$5.66M$7.91M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$290K$0.00$0.00
Total liabilities$19.4M$21.4M$10.1M$5.66M$7.91M
Common stock$493.7M$464.4M$443.9M$158.2M$141.5M
Retained earnings-$-390.82M-$-339.37M-$-226.23M-$-148.15M-$-100.66M
Accumulated other comprehensive income (loss)$8.08M-$-7.23M-$-2.29M-$-2.04M-$-370K
Total equity$232.2M$237.2M$291.9M$48.2M$76.2M
Total investments$0.00$0.00$0.00$0.00$240K
Total debt$0.00$0.00$290K$0.00$0.00
Net debt-$-157.78M-$-135.02M-$-208.7M-$-16.63M-$-53.64M
Cash flow statement
20262025202420232022
Net income-$-147.05M-$-113.14M-$-78.08M-$-47.49M-$-67.63M
Depreciation and amortization$120K$470K$420K$250K$170K
Stock-based compensation$0.00$42.9M$13.9M$4.69M$18M
Change in working capital-$-1.25M-$-9.79M-$-5.03M-$-1.44M$210K
Accounts receivable-$-930K-$-1.41M-$-1.09M-$-950K-$-770K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-132.42M-$-101.3M-$-68.91M-$-47.43M-$-45.21M
Investments in property, plant and equipment-$-1.36M-$-1.97M-$-710K-$-140K-$-100K
Acquisitions, net$10K$0.00$7.63M$0.00$0.00
Net cash used for investing activities-$-1.35M-$-1.97M$6.92M-$-3.31M-$-770K
Common stock issued$172.8M$20.5M$254.7M$13.6M$35.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$197M$20.2M$254.5M$13.6M$35.8M
Net change in cash$64M-$-73.97M$192.4M-$-37.01M-$-10.38M
Cash at end of period$157.8M$135M$209M$16.6M$53.6M
Operating cash flow-$-132.42M-$-101.3M-$-68.91M-$-47.43M-$-45.21M
Capital expenditure-$-1.36M-$-1.97M-$-710K-$-3.31M-$-520K
Free cash flow-$-133.79M-$-103.27M-$-69.62M-$-50.74M-$-45.73M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cybin Inc. Common Stock

        Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.

        CEO
        Eric So
        Employees
        100
        Beta
        0.56

        Explore

        Frequently asked questions

        What is the intrinsic value of Cybin Inc. Common Stock (HELP)?

        InvestorsCraft does not currently publish an intrinsic value for HELP. How the IC value is calculated.

        Is HELP undervalued?

        InvestorsCraft does not publish an undervaluation signal for HELP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.